Showing results (1-10 of 53) with videos related to
Sort By:
Pageof 6
Nature Reviews. Drug Discovery|November 6, 2012
EU-AIMS: a boost to autism researchDeclan Murphy, Will SpoorenDrug News & Perspectives|August 31, 2004
mGlu5 receptor antagonists: a novel class of anxiolytics?Will Spooren, Fabrizio GaspariniNature Reviews. Drug Discovery|December 13, 2005
Opinion: NK3 receptor antagonists: the next generation of antipsychotics?Will Spooren, Claus Riemer, Herbert MeltzerFrontiers in Psychiatry|December 15, 2016
Defining Precision Medicine Approaches to Autism Spectrum Disorders: Concepts and ChallengesEva Loth, Declan G Murphy, Will SpoorenTrends in Pharmacological Sciences|October 23, 2012
Synapse dysfunction in autism: a molecular medicine approach to drug discovery in neurodevelopmental disordersWill Spooren, Lothar Lindemann, Anirvan Ghosh, et al.European Journal of Pharmacology|June 1, 2007
Stress-induced hyperthermia: effects of acute and repeated dosing of MPEPRebecca E Nordquist, Sean Durkin, Georg Jaeschke, et al.European Journal of Pharmacology|October 22, 2008
The tachykinin NK3 receptor agonist senktide induces locomotor activity in male Mongolian gerbilsRebecca E Nordquist, Sean Durkin, Aurélie Jacquet, et al.Psychopharmacology|January 18, 2012
Further characterization of the prototypical nociceptin/orphanin FQ peptide receptor agonist Ro 64-6198 in rodent models of conflict anxiety and despairCelia Goeldner, Will Spooren, Jürgen Wichmann, et al.Current Opinion in Drug Discovery & Development|August 30, 2008
mGluR5 antagonists: discovery, characterization and drug developmentFabrizio Gasparini, Graeme Bilbe, Baltazar Gomez-Mancilla, et al.Neuron|December 3, 2014
Public-private partnership: a new engine for translational research in neurosciencesDeclan G M Murphy, Michel Goldman, Eva Loth, et al.Pageof 6